Cambridge Healthtech Institute's Third Annual Anti-inflammatories: Small Molecules Meeting, April 17^th – 18^th 2012, San Diego, USA

Bibliography

• Zinselmeyer BH, Dempster J, Gurney AM, In situ characterisation of CD4+ T cell behaviour in mucosal and systemic lymphoid tissues during the induction of oral priming and tolerance. J Exp Med 2005;201:1815–23
   PubMed Web of Science ®Google Scholar
• Celli SM, Lemaitre F, Bousso P. Real-time manipulation of T cell-dendritic cell interactions in vivo reveals the importance of prolonged contacts for CD4+ T cell activation. Immunity 2007;27:625–34
   PubMedGoogle Scholar
• Millington OR, Gibson VM, Rush CM, malaria impairs t cell clustering and immune priming despite normal signal 1 from dendritic cells. PLoS Pathogens 2007;3:1380–7
   PubMed Web of Science ®Google Scholar
• Rush CM, Millington OR, Hutchison S, Characterization of CD4+ T-cell–dendritic cell interactions during secondary antigen exposure in tolerance and priming. Immunology 2009;128:463–71
   PubMed Web of Science ®Google Scholar
• Gibson VB, Benson RA, Bryson KJ, A novel method to allow noninvasive, longitudinal imaging of the murine immune system in vivo. Blood 2012;119:2545–51
   Google Scholar
• Platt AM, Gibson VB, Patakas A, Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J. Immunol 2010;185:1558–67
   PubMed Web of Science ®Google Scholar
• Edmonds Y, Milstien S, Spiegel S. Development of small-molecule inhibitors of sphingosine-1-phosphate. Pharmacol Ther 2011;132:352–60
   PubMed Web of Science ®Google Scholar
• Kabashima K, Haynes NM, Xu Y, Plasma S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. J Exp Med 2006;203:2683–90
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Billich A, Baumruker T, Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883–97
   PubMed Web of Science ®Google Scholar
• Gergely P, Nuesselein-Hildesheim B, Guerini BD, The selective S1P receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate: translation from preclinical to clinical studies. Br J Pharmacol 2012; In press
   PubMedGoogle Scholar
• Choi JW, Gardell SE, Herr DR, FTY720 (Fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 2011;108:751–6
   PubMed Web of Science ®Google Scholar
• Jackson SJ, Giovanni G, Baker D. Fingolimod modulates microglial activation to augment markers of remyelination. J. Neuroinflammation 2011;8:76
   PubMed Web of Science ®Google Scholar
• Cui QL, Fang J, Almazan G, Sphingosine 1-phosphate receptor agonists promote axonal ensheathment by human fetal oligodendrocyte progenitors. Mult Scler 2011;17(10 Suppl):823
   Google Scholar
• Selmaj K, Li D, Stuve O, BAF312, a selective sphingosine 1-phosphate receptor modulator, effectively suppresses MRI lesion activity in relapsing-remitting multiple sclerosis: findings of the adaptive dose-ranging phase 2 study. Mult Scler 2011;17(10 Suppl):1107
   PubMedGoogle Scholar
• Hirai HK, Tanaka O, Yoshie K, Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils and basophils via seven trans-membrane receptor CRTh2. J Exp Med 2001;193:255–61
   PubMed Web of Science ®Google Scholar
• Nagata KH, Hirai K, Tanaka K, CRTh2 and orphan receptor of T-helper-2-cells is expressed on basophils and eosinophils and responds to mast cell derived factor(s). FEBS Lett 1999;459:195–9
   PubMed Web of Science ®Google Scholar
• Xue LSL, Gyles FR, Wettey L, Prostaglandin D2 causes preferential induction of proinflammatorty Th2 cytokine production through anaction on chemoattractant receptor like molecule expressed on Th2 cells. J Immunol 2005;175:6531–6
   PubMed Web of Science ®Google Scholar
• Chen JJ, Budelsky AL. Prostaglandin D2 receptor CRTh2 antagonists for the treatment of inflammatory diseases. Prog Med Chem 2011;50:49–107
   PubMedGoogle Scholar
• Burgess L, Anderson L, Nugent C, Safety, PK and PD of ARRY-502, a CRTh2 antagonist, in healthy subjects with a history of seasonal allergies [abstract 59]. 2010. p. S287
   Google Scholar
• Stanbury RM, Graham EM. Systemic corticosteroid therapy-side effects and their management. Br J Opthalmol 1998;82:704–8
   PubMed Web of Science ®Google Scholar
• Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol 2010;24:157–65
   PubMed Web of Science ®Google Scholar
• Berlin M. Recent adbances in the development of novel glucocortocid receptor modulators. Expert Opin Ther Patents 2010;20:855–73
   PubMed Web of Science ®Google Scholar
• Reichardt HM, Kaestner KH, Tuckermann J, DNA binding of the glucocortocid receptor is not essential for survival. Cell 1998;93:531–41
   PubMed Web of Science ®Google Scholar
• Reichardt HM, Tronche F, Bauer A, Molecular genetic analysis of glucocortocoid signaling using the Cre/loxP system. Biol Chem 2000;381:9–10
   Web of Science ®Google Scholar
• Stock T, Fleishaker D, Mukherjee A, Evaluation of safety, pharmacokinetics and pharmacodynamics of a selective glucocorticoid receptor modulator (SGRM) in healthy volunteers. Arthritis Rheum 2009;60:420
   Google Scholar
• Mukherjee A, Ku J, Fleishaker D, Quantitative estimation of dissociation of a selective glucocortocid modulator PF-00251802 in healthy volunteers. Clin Pharm Ther 2010;87:S57
   PubMed Web of Science ®Google Scholar
• Hoth M, Penner R. Depletion of intracellular calcium stores activates a calcium current in mast cells. Nature 1992;355:353–6
   PubMed Web of Science ®Google Scholar
• Roos J, Digregorio PJ, Yeromin AV, STIM1, an essential and conserved component of store-operated Ca2+ channel function. J Cell Biol 2005;169:435–45
   PubMed Web of Science ®Google Scholar
• Feske S, Gwack Y, Prakriya M, A mutation in ORA1 causes immune deficiency by abrogating CRAC channel function. Nature 2006;441:179–85
   PubMed Web of Science ®Google Scholar
• Crabtree GR. Calcium, calcineurin and the control of transcription. J Biol Chem 2001;276:2313–16
   PubMed Web of Science ®Google Scholar
• Partiseti M, Le Deist F, Hivroz C, The calcium current activated by T cell receptor and store depletion in human lymphocytes is absent in a primary immunodeficiency. J Biol Chem 1994;269:32327–35
   PubMed Web of Science ®Google Scholar
• Feske S, Giltnane J, Dolmetsch R, Gene regulation by calcium influx in T-lymphocytes. Nat Immunol 2001;2:316–24
   PubMed Web of Science ®Google Scholar
• Boyce JA. Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol Rev 2007;217:168–85
   PubMed Web of Science ®Google Scholar
• Weller CL, Collington SJ, Brown KJ, Leukotriene B4, an activation product of mast cells, is a chemoattractant for their progenitors. J Exp Med 2005;201:1961–71
   PubMed Web of Science ®Google Scholar
• Tager AM, Bromley SK, Medoff BD, Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003;4:982–90
   PubMed Web of Science ®Google Scholar
• Montuschi P, Barnes PJ. Exhaled leukotrienes and prostaglandins in asthma. J Allergy Clin Immunol 2002;109:615–20
   PubMed Web of Science ®Google Scholar
• Zaitsu M, Hamasaki Y, Matsuo M, Leukotriene synthesis is increased by transcriptional up-regulation of 5-lipoxygenase, leukotriene A4 hydrolase and leukotriene C4 synthase in asthmatic children. J Asthma 2003;40:147–54
   PubMed Web of Science ®Google Scholar
• Rao NL, Riley JP, Banie H, Leukotriene A4 hydrolase inhibition attenuates allergic airway inflammation and hyperresponsiveness. Am J Respir Crit Care Med 2010;181:899–907
   PubMed Web of Science ®Google Scholar
• Whittle BJ, Varga C, Berko A, Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase. Br J Pharmacol 2008;153:983–1
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signalling. Immunol Rev 2009;1:273–87
   Web of Science ®Google Scholar
• Leonard WJ, O'Shea JJ. JAKs and STATs: biological implications. Annu Rev Immunol 1998;16:293–322
   PubMed Web of Science ®Google Scholar
• Williams NK, Barnert RS, Patel O, Dissecting specificity in the janus kinases: the structures of JAK specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol 2009;387:219–32
   PubMed Web of Science ®Google Scholar
• Chrencik JE, Patny A, Leung IK, Structural and thermodynamic characterisation of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol 2010;400:413–33
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, A quantitative analysis of kinase inhibitor activity. Nat Biotechnol 2008;26:127–32
   PubMed Web of Science ®Google Scholar
• Meyer DM, Jesson MI, Li X, Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm 2010;7:41
   Google Scholar
• Ghoreschi K, Jesson MI, Li X, Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186:4234–43
   PubMed Web of Science ®Google Scholar
• Belli B, Bringham D, Dao A, AC430, a potent JAK2 inhibitor, provides protection in multiple inflammatory and autoimmune disease models. Arthritis Rheum 2010;62(Suppl 10):269
   Google Scholar
• Singh R, Masuda ES, Payan DG. Discovery and development of spleen tyrosine kinase (SYK) inhibitors. J Med Chem 2012; In press
   Google Scholar
• Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological function. Nat Rev Immunol 2010;10:387–402
   PubMed Web of Science ®Google Scholar
• Ulanova M, Duta F, Puttagunta L, Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis. Expert Opin Ther Targets 2005;9:901–21
   PubMed Web of Science ®Google Scholar
• Masuda ES, Schmitz J. Syk inhibitors as treatment for allergic rhinitis. Pulmon Pharmacol Ther 2008;21:461–7
   PubMed Web of Science ®Google Scholar
• Havrad S, Scola A-M, Kay LJ, Characterisation of syk expression in human lung mast cells: relationship with function. Clin Exp Allergy 2011;41:378–88
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Fossati G, Mascagni P. HDAC inhibitors for treating of a spectrum of diseases not related to cancer. Mol Med 2011;17:333–52
   PubMed Web of Science ®Google Scholar
• Bode KA, Dalpke AH. HDAC inhibitors block innate immunity. Blood 2011;117:1102–3
   PubMed Web of Science ®Google Scholar
• Shuttleworth SJ, Silva FA, Cecil ARL, Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem 2011;18:2686–714
   PubMed Web of Science ®Google Scholar
• Shuttleworth SJ, Bailey SG, Townsend P. Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory disease. Curr Drug Targets 2010;11:1430–8
   PubMed Web of Science ®Google Scholar
• De Zoeten EF, Wang L, Butler K, Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol 2011;10:2066–78
   Web of Science ®Google Scholar
• Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, The emerging mechanism of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11:329–41
   PubMed Web of Science ®Google Scholar
• Bartok B, Boyle DL, Liu Y, PI3K kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis. Am J Pathol 2012;180:1906–16
   PubMed Web of Science ®Google Scholar
• Utsugi M, Dobashi K, Ono A, PI3K p110β positively regulates lipopolysaccharide-induced IL12 production in human macrophages and dendritic cells and JNK1 plays a novel role. J Immunol 2009;182:5225–31
   PubMed Web of Science ®Google Scholar
• Boyle KB, Gyori D, Sindrilau A, Class IA phosphoinositide 3-kinase beta and delta regulate neutrophil oxidase activation in response to aspergillus fumigatus hyphae. J Immunol 2011;186:2978–89
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Sitaru S, Jakus Z, PI3Kβ plays a critical role in neutrophil activation by immune complexes. Sci Signal 2011;4:ra23
   PubMed Web of Science ®Google Scholar
• Pan Z, Scheerens H, Li SJ, Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem Med Chem 2007;2:58–61
   Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, The bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010;107:13075–80
   PubMed Web of Science ®Google Scholar
• Lou Y, Owens TD, Kugslatter A, Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem 2012; in press
   PubMed Web of Science ®Google Scholar
• Evans E, Karp R, Tester R, Covalent inhibition of Btk with clinical development compound AVL-292 disrupts signalling that maintains the microenvironment necessary for chronic lymphocytic leukemia growth. Clin Lymphoma, Myeloma & Leuk 2011;11:S173–4
   Google Scholar
• Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006; 2006:re13
   Google Scholar
• Catley MC, Sukkar MB, Chung KF, Validation of the anti-inflammatory properties of small-molecule IkB kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Mol Pharmacol 2006;70:697–705
   PubMed Web of Science ®Google Scholar
• Suzuki J-I, Ogawa M, Mutto S, Novel IκB kinase inhibitors for treatment of nuclear factor-κB-related diseases. Expert Opin Investig Drugs 2011;20:395–405
   PubMed Web of Science ®Google Scholar
• Morwick T, Berry A, Brickwood J, Evolution of the thienopyridine class of inhibitors of IkB kinase-β. Part 1: hit-to-leasd strategies. J Med Chem 2006;49:2898–908
   PubMed Web of Science ®Google Scholar
• Wu J-P, Fleck R, Brickwood J, The discovery of novel thienopyridine analogs as potent IκB kinase inhibitors. Part II. Bioorg Med Chem Lett 2009;19:5547–51
   PubMed Web of Science ®Google Scholar
• Clark K, Peggie M, Plater L, Novel cross-talk within the IKK family controls innate immunity. Biochem J 2011;434:93–104
   PubMed Web of Science ®Google Scholar
• Huber MA, Maier HJ, Alacakaptan M, BI5700, a selective chemical inhibitor of IκB kinase 2, specifically suppresses epithelial-mesenchymal transition and metastasis in mouse models of tumour progression. Genes Cancer 2010;1:101–14
   PubMedGoogle Scholar
• Chen Z, Hagler J, Palombella VJ, Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 1995;9:1586–97
   PubMed Web of Science ®Google Scholar